IFLO vs IART โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IART Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Integra LifeSciences Holdings (IART) driven by superior Valuation, Growth & Margin, Options & Structure while IFLO counters with relative strength in Momentum & Technical. Fundamentally, IFLO trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus IART at 5.6x Forward P/E and 9.9% operating margin (+2.3% YoY). In options structure, IFLO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against IART sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IFLO | IART | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $1.1B | Larger Scale | IART |
| Trailing P/E Ratio Valuation | N/M | 79.7x | Lower Multiple | IART |
| Forward P/E Ratio Valuation | N/M | 5.6x | Lower Multiple | IART |
| Revenue Growth (YoY) Growth | N/A | +2.3% | Higher Growth | IART |
| Operating Margin (TTM) Profitability | N/A | 9.9% | Higher Margin | IART |
| Net Profit Margin Profitability | N/A | 0.8% | Higher Margin | IART |
| Return on Equity (ROE) Capital Efficiency | N/A | 1.2% | Higher ROE | IART |
| 52-Week Range Position Momentum | 63% ($27โ$38) | 39% ($9โ$20) | Stronger Trend | IFLO |
| Beta / 30D Volatility Risk Regime | 0.76ฮฒ ยท 18% Vol | 1.54ฮฒ ยท 60% Vol | Lower Realized Risk | IFLO |
| Unified Institutional Score Composite Signal | 35.7 / 100 (SELL) | 45.5 / 100 (HOLD) | Higher Composite | IART |